The US Food and Drug Administration would be authorized to require companies developing new combinations of cancer drugs to conduct pediatric studies under an amendment to user fee reauthorization legislation adopted by the House Energy & Commerce Committee.
At its 18 May markup of the measure, the committee voted unanimously in favor of an amendment by Rep. G.K....







